Literature DB >> 22941944

AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method.

Marie-Françoise Klucker1, François Dalençon, Patricia Probeck, Jean Haensler.   

Abstract

AF03 is a squalene-based emulsion adjuvant that is present in the adjuvanted pandemic influenza vaccine, Humenza™. In this report, we describe the design and development of this novel adjuvant formulation from the selection of the oil and surfactant system used in the adjuvant composition to the phase inversion temperature emulsification process that afforded AF03 as a long-term stable and well calibrated oil-in-water emulsion. The emulsion was characterized by its particle sizes, surface and interfacial tensions, viscosity, and long-term stability.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22941944     DOI: 10.1002/jps.23311

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

Review 1.  Adjuvanted influenza vaccines.

Authors:  John S Tregoning; Ryan F Russell; Ekaterina Kinnear
Journal:  Hum Vaccin Immunother       Date:  2018-01-25       Impact factor: 3.452

Review 2.  Clinical vaccine development for H5N1 influenza.

Authors:  Christopher H Clegg; Joseph A Rininger; Susan L Baldwin
Journal:  Expert Rev Vaccines       Date:  2013-07       Impact factor: 5.217

3.  Impact of formulation and particle size on stability and immunogenicity of oil-in-water emulsion adjuvants.

Authors:  Vidyashankara Iyer; Corinne Cayatte; Bernardo Guzman; Kirsten Schneider-Ohrum; Ryan Matuszak; Angie Snell; Gaurav Manohar Rajani; Michael P McCarthy; Bilikallahalli Muralidhara
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle.

Authors:  Jennifer N Rainho-Tomko; Vincent Pavot; Michael Kishko; Kurt Swanson; Darin Edwards; Heesik Yoon; Lilibeth Lanza; Judith Alamares-Sapuay; Robert Osei-Bonsu; Sophia T Mundle; Dave A Murison; Scott Gallichan; Simon Delagrave; Chih-Jen Wei; Linong Zhang; Gary J Nabel
Journal:  NPJ Vaccines       Date:  2022-06-30       Impact factor: 9.399

5.  PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.

Authors:  Alice Gaudin; Eric Song; Amanda R King; Jennifer K Saucier-Sawyer; Ranjit Bindra; Didier Desmaële; Patrick Couvreur; W Mark Saltzman
Journal:  Biomaterials       Date:  2016-08-04       Impact factor: 12.479

6.  A novel vaccine adjuvant based on straight polyacrylate potentiates vaccine-induced humoral and cellular immunity in cynomolgus macaques.

Authors:  Vincent Pavot; Hélène Bisceglia; Florine Guillaume; Sandrine Montano; Linong Zhang; Florence Boudet; Jean Haensler
Journal:  Hum Vaccin Immunother       Date:  2021-01-10       Impact factor: 3.452

7.  Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial.

Authors:  Leigh M Howard; Kristen L Hoek; Johannes B Goll; Parimal Samir; Allison Galassie; Tara M Allos; Xinnan Niu; Laura E Gordy; C Buddy Creech; Nripesh Prasad; Travis L Jensen; Heather Hill; Shawn E Levy; Sebastian Joyce; Andrew J Link; Kathryn M Edwards
Journal:  PLoS One       Date:  2017-01-18       Impact factor: 3.240

8.  Nanocarrier vaccines for SARS-CoV-2.

Authors:  Jatin Machhi; Farah Shahjin; Srijanee Das; Milankumar Patel; Mai Mohamed Abdelmoaty; Jacob D Cohen; Preet Amol Singh; Ashish Baldi; Neha Bajwa; Raj Kumar; Lalit K Vora; Tapan A Patel; Maxim D Oleynikov; Dhruvkumar Soni; Pravin Yeapuri; Insiya Mukadam; Rajashree Chakraborty; Caroline G Saksena; Jonathan Herskovitz; Mahmudul Hasan; David Oupicky; Suvarthi Das; Ryan F Donnelly; Kenneth S Hettie; Linda Chang; Howard E Gendelman; Bhavesh D Kevadiya
Journal:  Adv Drug Deliv Rev       Date:  2021-01-09       Impact factor: 17.873

9.  Short-Course Treatment With Imipramine Entrapped in Squalene Liposomes Results in Sterile Cure of Experimental Visceral Leishmaniasis Induced by Antimony Resistant Leishmania donovani With Increased Efficacy.

Authors:  Sandip Mukherjee; Supratim Pradhan; Souradeepa Ghosh; Shyam Sundar; Shantanabha Das; Budhaditya Mukherjee; Syamal Roy
Journal:  Front Cell Infect Microbiol       Date:  2020-11-10       Impact factor: 5.293

Review 10.  Squalene-Based Influenza Vaccine Adjuvants and Their Impact on the Hemagglutinin-Specific B Cell Response.

Authors:  Phuong Nguyen-Contant; Mark Y Sangster; David J Topham
Journal:  Pathogens       Date:  2021-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.